Beta-2 Polymorphisms and Beta Receptor Selectivity
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
We hypothesize that b2 adrenergic polymorphisms affect b-receptor selectivity in patients
with heart failure treated with either a b1-selective or a b-nonselective agent. b-2
polymorphisms may contribute to differing responses to drug treatment with beta-blockers in
heart failure. Characterizing these polymorphisms may help explain the variability in the
degree of "selectivity" of action of b-blockers at the b receptor, namely if their action is
specific for the b-1 or b-2 receptor. Part A was conducted at the University of Utah, and all
subjects completed study related activities. Part B (sub-study) consists of genotyping of
blood samples collected in part A, which will be completed at the University of Wisconsin.
Sub-study (samples and DNA isolation) or Part B entailed analyzing an extra 10 mL of blood
that was taken for DNA isolation. Genotyping (i.e. determination of genetic makeup) of beta
adrenergic polymorphisms utilized polymerase chain reaction followed by pyrosequencing.